Evidence map›Paper›PMID 30569227›Full record

ArticleNanoscale research letters2018

Ruthenium-containing supramolecular nanoparticles based on bipyridine-modified cyclodextrin and adamantyl PEI with DNA condensation properties.

Fang Yan, Jian-Shuang Wu, Zhi-Li Liu, Hong-Li Yu, Yong-Hong Wang, Wei-Fen Zhang, De-Jun Ding

Abstract read
In one paragraph

Article in Nanoscale research letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fang YanCollege of Pharmacy, Weifang Medical University, Weifang, 261053, Shandong, China.
Jian-Shuang WuCollege of Pharmacy, Weifang Medical University, Weifang, 261053, Shandong, China.
Zhi-Li LiuCollege of Pharmacy, Weifang Medical University, Weifang, 261053, Shandong, China.
Hong-Li YuCollege of Pharmacy, Weifang Medical University, Weifang, 261053, Shandong, China.
Yong-Hong WangCollege of Pharmacy, Weifang Medical University, Weifang, 261053, Shandong, China.
Wei-Fen ZhangCollege of Pharmacy, Weifang Medical University, Weifang, 261053, Shandong, China. zhangwf@wfmc.edu.cn.
De-Jun DingCollege of Pharmacy, Weifang Medical University, Weifang, 261053, Shandong, China. dejunding@wfmc.edu.cn.

Funding

National Natural Science Foundation of China No. 81774125Scientific Research and Development Project of Shandong Provincial Education Department No. J18KA279
6 · The paper itself

Abstract

Exploring safe and highly efficient gene carriers made from biocompatible constituents has great prospects for clinical gene therapy. Here, a supramolecular gene delivery system was readily constructed by assembling adamantyl-modified polyethylenimine (PEI-Ada) units with a versatile ruthenium bipyridine-modified cyclodextrin (Ru-CD) through host-guest interactions. The photophysical and morphological features of the PEI-Ada@Ru-CD nanoparticles were systematically characterized by techniques including UV-vis absorption spectroscopy, fluorescence spectroscopy, transmission electron microscopy, dynamic light scattering, and zeta potential experiments. The small size and suitably positive zeta potential of the nanoparticles facilitated their cellular uptake and gene transfection. As expected, DNA interaction studies, which were performed using agarose gel electrophoresis and atomic force microscopy, showed that the ability of the nanoparticles to condense DNA was higher than that of the gold standard, i.e., PEI, at low N/P ratios. The design of these ruthenium-containing supramolecular nanoparticles based on bipyridine-modified cyclodextrin and adamantyl PEI has great prospects in the development of gene delivery vehicles.

Indexed as

CyclodextrinNon-viral gene delivery vectorRuthenium complexesSelf-assemblySupramolecular chemistry

Identifiers

PMID30569227
PMCPMC6300456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.